Digital PCR Market Size Expected to Reach USD 17.45 Bn by 2034

The global digital PCR market size is calculated at USD 7.82 billion in 2025 and is expected to reach around USD 17.45 billion by 2034, growing at a CAGR of 9.33% for the forecasted period.

/EIN News/ -- Ottawa, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The global digital PCR market size was valued at USD 7.15 billion in 2024 and is predicted to hit around USD 15.96 billion by 2033, a study published by Towards Healthcare a sister firm of Precedence Statistics.

Get All the Details in Our Solutions – Download Brochure: https://www.towardshealthcare.com/download-brochure/5367

Market Overview and Key Statistics

Clonal acid strands can be immediately quantified and amplified using digital PCR (dPCR), a variation of traditional PCR techniques. By delivering an absolute count of target DNA copies per input sample without the need to run standard curves, dPCR has several advantages over traditional PCR techniques.

Some of the major drivers anticipated to propel the digital PCR market expansion during the forecast period are the launch of products, an increase in acquisitions, the increased use of technology by laboratories, and the rise in the incidence of infectious illnesses, cancer, and genetic disorders. Furthermore, it is anticipated that growing technical developments in digital devices will support market expansion throughout the course of the projection period. By 2025, 585 million more individuals worldwide—just over halfway to the 1 billion target—are anticipated to have access to basic health care without incurring catastrophic health costs, and 777 million more are anticipated to have improved health emergency protection. By 2025, an estimated 1.5 billion more people will live healthier lives thanks to healthier populations, which offer the only bright light.

Driving Factors for Market Growth

Increased usage of chip-based test

A key factor in the development of the devices has been the switch from droplet to chip-based diagnostics for the detection of different illnesses. Because the droplets in commercially available droplet digital test kits must be manually transferred, the objectives are underestimated. Additionally, there is a chance of cross-contamination while the sample is being transferred using ddPCR kits. Additionally, ddPCR has a number of drawbacks, including the unpredictability of droplet size and shape, which compromises the method's robustness and repeatability. A lengthy procedure and the need for qualified experts are only two of the additional restrictions.

Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

Technological advancements

The advancement of traditional technology that allows for the direct clonal amplification and quantification of nucleic acids is the digital polymerase chain reaction. Numerous PCR technologies with significant advantages have been introduced as a result of increased research and development efforts and the rising need for novel devices. The market is expected to increase as a result of major companies introducing novel devices based on droplet, chip-based, beam, and crystal response approaches.

Rise in the usage of personalized medicine.

According to the Tailored Medicine Coalition (PMC), the number of tailored therapies has significantly expanded from 2008, when there were just five personalized medications accessible. There are already more than 145 personalized treatments on the market as a result of growing awareness and acceptance of individualized medications. Additionally, the number of tailored medications is growing as the FDA quickly authorizes additional procedures and therapies that can offer more efficient and successful healthcare. Additionally, diagnostic testing helps determine each patient's optimal course of therapy.

Regional Insights

Technological advancements are driving North America.

North America held the largest share of the digital PCR market in 2024. because of its well-established biotechnology industry, significant R&D expenditures, and the sophisticated healthcare system. The area's widespread use of technology in a variety of applications, such as cancer research, infectious illnesses, and tailored medicine, has solidified its position as the market leader in this sector. The area is strong for competitive reasons thanks to renowned research institutes and major market participants such as F. Hoffmann-La Roche AG and Thermo Fisher Scientific. The financing and legal backing provided to cutting-edge medical solutions is another factor contributing to North America's continued dominance of the digital PCR business.

Because of the high incidence of chronic illnesses, including cancer, heart disease, and infectious diseases, the US digital PCR market had the most market share in 2024. The need for dPCR in clinical diagnostics is driven by its accuracy and sensitivity, which make it a vital tool for early diagnosis, illness monitoring, and individualized therapy. The market is further supported by prominent businesses like Qiagen, Thermo Fisher Scientific, and Bio-Rad Laboratories. The stability and expansion of the digital PCR market are assured by their wide distribution networks and ongoing product improvements.

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Rising healthcare expenditure is driving the Asia Pacific.

Asia Pacific is expected to host the fastest-growing digital PCR market during the forecast period. The expanding population, growing healthcare expenses, and growing awareness of the need for early illness detection have all contributed to the strong demand for advanced molecular diagnostic procedures. The use of digital PCR is further promoted by China and India, two countries that have made significant investments in biotechnology and genomics research. The region's growing biotech and pharmaceutical industries foster innovation and collaboration by creating a strong ecosystem. Because of this, the digital PCR market in Asia-Pacific is expected to expand at a never-before-seen pace and eventually capture a sizable portion of the worldwide market in the years to come.

Market Segmentation

By type, the droplet digital PCR segment dominated the digital PCR market in 2024. Compared to other commercially available digital PCR systems, this approach requires a reduced sample size, which lowers costs and preserves valuable samples.

By type, the chip-based digital PCR segment is expected to grow significantly during the forecast period. One of the many benefits of cdPCR is its quick partitioning. Use of reagents and samples in modest quantities. A single gadget can incorporate several responses.

By product, the instruments segment dominated the digital PCR market in 2024. The market participants' growing efforts to introduce new goods and expand the use of this gadget in the marketplace are responsible for the segment's greatest share.

By product, the reagents and consumables segment is anticipated to grow at the fastest CAGR during the forecast period. The growing commercialization of these digital device kits for diagnostic reasons is the reason for the segment's rise. For example, QIAGEN unveiled new QIAcuity digital PCR kits for food safety and biopharmaceutical clients in November 2023.

By indication, the genetic disorders segment held the major share of the digital PCR market in 2024. With over 7000 different kinds of rare diseases, the global burden is not negligible. Currently, 300 million individuals suffer from uncommon illnesses. Nearly 70% of uncommon diseases manifest in childhood, and roughly 80% have a genetic basis. Of these, 95% do not currently have authorized therapies.

By indication, the oncology segment is anticipated to grow substantially in the market during the forecast period. The anticipated 20 million new cases of cancer in 2022 are expected to rise by 77% to over 35 million cases in 2050. The world's fast-increasing cancer burden is a result of both population expansion and aging, as well as shifts in risk factor exposure.

By end-user, the academic and research organizations segment dominated the digital PCR market in 2024. The growing usage of these devices in research studies across a range of disciplines, such as genetic illnesses and cancer, is responsible for the segment's rise.

By end-user, the clinical laboratories segment is expected to grow at the fastest CAGR in the market during the forecast period. The rising incidence of infectious illnesses and the growing usage of these digital tools for disease diagnostics are the main drivers of this segment's growth.

By application, the clinical segment held the largest share of the digital PCR market in 2024. Digital PCR is highly used in various disease diagnoses, which makes it a valuable technique in the clinical segment.

By application, the research segment is expected to grow at the fastest rate in the market during the forecast period. For the measurement of nucleic acids, researchers in the fields of genetics, molecular biology, and medicinal sciences require accurate instruments. The research segment of the digital PCR market is driven by the precision and sensitivity of digital PCR, which makes it perfect for research applications.

Competitive Landscape

QIAGEN (Germany), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), JN Medsys (Singapore), Stilla (France), Sysmex Corporation (Japan), Standard BioTools Inc. (U.S.), and Precigenome LLC. (U.S.).

• Johnson & Johnson (J&J), a global healthcare corporation with its headquarters located in the United States, operates in two business sectors: Innovative Medicine and MedTech. The company's market worth, as of April 18, 2024, is $351.2 billion. Innovative Medicine and MedTech may be responsible for $54.8 billion and $30.4 billion of J&J's $85.2 billion in 2023 sales, respectively.
• AstraZeneca is investing $300 million in a state-of-the-art laboratory in Rockville, Maryland, in February 2024 to launch its life-saving cell therapy platforms in the US for significant cancer research and possible commercial supply.

Browse More Insights of Towards Healthcare:

• The global biological PCR technology market was valued at $13.69 billion in 2023 and is projected to reach $28.93 billion by 2034, growing at a CAGR of 7.04%.
• The global healthcare CRM market is estimated at $19.29 billion in 2024 and is expected to grow to $40.64 billion by 2034, with a CAGR of 7.74%.
• The behavioral rehabilitation market will expand from $165.94 billion in 2024 to $235.89 billion by 2034, at a CAGR of 3.58%.
• The dental services market is projected to increase from $499.21 billion in 2025 to $769.8 billion by 2034, growing at a CAGR of 4.93%.
• The cold storage market is forecast to rise from $172.98 billion in 2025 to $479.69 billion by 2034, with a CAGR of 12%.
• The hospital outsourcing market is valued at $381.74 billion in 2024 and will grow to $1,021.17 billion by 2034, expanding at a CAGR of 10.34%.
• The women’s health app market is estimated at $4.89 billion in 2024 and is expected to reach $25.18 billion by 2034, with a CAGR of 17.81%.
• The mHealth market will grow from $79.06 billion in 2025 to $260.56 billion by 2034, driven by a CAGR of 14.17%.
• The home healthcare market will expand from $226.92 billion in 2025 to $476.80 billion by 2034, with a CAGR of 8.6%.
• The global health and wellness market is projected to rise from $6.16 trillion in 2025 to $9.94 trillion by 2034, growing at a CAGR of 5.46%.

Recent Developments

• In January 2025, with a more than twofold increase in the number of targets that can be evaluated concurrently from a single biological sample, QIAGEN announced a major expansion of the potent capabilities of its QIAcuity Digital PCR (dPCR) instrument.
• In October 2024, QGEN introduced the QIAcuityDx Digital PCR System, whose components and instrument are authorized by the Food and Drug Administration ("FDA") 510(k) and certified for diagnostic usage in Europe by the In Vitro Diagnostic Regulation ("IVDR").
• In February 2023, the start-up pioneering digital PCR advancements, Stilla Technologies, reported closing a $26.5 million Series C funding round.
  

Segments Covered in the Report

By Type

• Droplet Digital PCR
• Chip-based Digital PCR
• Others
  

By Products

• Instruments
• Reagents & Consumables
• Software & Services
  

By Indication

• Infectious Diseases
• Oncology
• Genetic Disorders
• Others

By End-user

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Industries
• Clinical Laboratories
• Academic & Research Organizations

By Application

• Clinical
• Research
• Forensic
  

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
    

Discover our detailed Table of Contents (TOC) for the Digital PCR Market @ https://www.towardshealthcare.com/table-of-content/digital-pcr-market-sizing

Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5367

You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com

Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

Browse our Brand-New Journals:

https://www.towardspackaging.com

https://www.towardsautomotive.com 

https://www.precedenceresearch.com

https://www.towardsdental.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com